Accessibility Menu
Celcuity logo

Celcuity

(NASDAQ) CELC

Current Price$88.68
Market Cap$4.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+540%
5 Year+334%
1 Year+564%
1 Month+4%
Celcuity last closing stock price
MetricPriceDate
Last closeUSD 91.512026-07-15
Celcuity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.97%USD 108.902026-07-08
1 month+3.71%USD 88.242026-06-15
3 month-26.94%USD 125.252026-04-16
Year to date-8.25%USD 99.742025-12-31
1 year+564.08%USD 13.782025-07-15
3 year+851.25%USD 9.622023-07-14
5 year+333.9%USD 21.092021-07-16
Since inception+540.38%USD 14.292017-09-20

Celcuity Financials at a Glance

Market Cap

$4.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$192.89M

EPS (TTM)

-$3.90

P/E Ratio

-23.48

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$88.68

Volume

3,362,976

Open

$91.69

Previous Close

$88.29

Daily Range

$84.99 - $91.69

52-Week Range

$13.47 - $151.02

Estimated Earnings Date

Aug 13, 2026

CELC News

Two people participating in a telehealth session

Why Celcuity Stock Popped on Monday

Eric VolkmanApr 27, 2026
Person in a lab gazing into a microscope

Why Celcuity Stock Popped Today

Eric VolkmanMar 26, 2026
BuyAlert-Purple.png

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

Jonathan PoncianoMar 13, 2026
SellAlert-Red.png

Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing

Jake LerchMar 10, 2026
BuyAlert-Green.png

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing

Jake LerchMar 6, 2026
BuyAlert-Blue.png

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

Jonathan PoncianoFeb 22, 2026
f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

Soleus Adds a Significant Number of Celcuity Shares

Lawrence Rothman, CFAFeb 13, 2026

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump

Sarah SidlowFeb 6, 2026
Page 1

CELC: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celcuity

Celcuity develops cancer therapies and diagnostic tests for patients and doctors. Its main drug and test help match treatments to each patient’s tumor. These tools aim to improve care for people with advanced cancers.

Products and Services

  • Gedatolisib (Drug Candidate): Intravenous therapy for advanced breast and prostate cancer; not yet approved; 0% of revenue.
  • CELsignia Diagnostic Platform: Lab test using live tumor cells to identify abnormal cell activity; 0% of revenue.
  • CELsignia MP Test: Measures specific cancer cell signals in breast and ovarian tumors; 0% of revenue.
  • Clinical Trial Programs: Focused on hormone receptor-positive, HER2-negative breast cancer and advanced prostate cancer; 0% of revenue.
  • Research and Development Services: All activities support drug and diagnostic development; 0% of revenue.

Growth and Expansion

  • Signed exclusive global license with Pfizer for gedatolisib in 2021.
  • Expanded clinical programs to prostate cancer in 2024.
  • Launched Phase 3 VIKTORIA-1 breast cancer trial in December 2022; completed PIK3CA WT cohort enrollment in the fourth quarter of 2024, and PIK3CA MT cohort enrollment is ongoing as of early 2026.
  • Initiated Phase 3 VIKTORIA-2 trial for first-line breast cancer in 2025.
  • Signed lease for new laboratory and office space in 2025, starting April 2026.

What Makes Celcuity Stand Out

Celcuity’s approach combines targeted drug development with diagnostic testing using live tumor cells. Its main drug candidate blocks multiple cancer cell pathways at once, aiming to overcome resistance. The company holds exclusive global rights to its lead therapy, supporting its position in targeted cancer treatment.

Five Things You Need to Know

  • No revenue reported for 2025, unchanged from previous years.
  • Net loss was $177.0 million in 2025, up 58% from 2024.
  • Research and development expenses reached $145.0 million in 2025, up 39% year-over-year.
  • Cash, cash equivalents, and short-term investments totaled $441.5 million at year-end 2025.

Bottom Line

Celcuity remains focused on developing targeted cancer therapies and diagnostics. The company’s future depends on successful drug approval and commercialization.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

155

CEO

Brian F. Sullivan

Website

www.celcuity.com

Headquarters

Minneapolis, MN 55446, US

CELC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-244.61%

Return on Capital

-58.19%

Return on Assets

-47.03%

Earnings Yield

-4.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.77M

Volume

3.36M

Avg. Volume

1.53M

Financials (TTM)

Gross Profit

-$47.00K

Operating Income

-$186.57M

EBITDA

-$172.66M

Operating Cash Flow

-$172.49M

Capital Expenditure

-$438.00K

Free Cash Flow

-$172.93M

Cash & ST Invst.

$145.19M

Total Debt

$195.58M

Celcuity Performance Analysis

Celcuity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Celcuity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Celcuity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.6218.4%
20232023-12-31USD -2.692.9%
20242024-12-31USD -2.835.2%
20252025-12-31USD -3.7933.6%
Celcuity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-20.9%
Q32025-09-3011.5%
Q42025-12-31-4.3%
Q12026-03-31-1.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$47.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.46BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$28.79M

N/A

Employees

155

N/A

Net Income

-$52.84M

-42.8%

EBITDA

-$46.71M

-38.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$145.19M

-29.4%

Total Debt

$195.58M

+98.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$195.57M

+98.5%

Short Term Debt

$13.00K

-92.3%

Return on Assets

-47.03%

N/A

Return on Invested Capital

-49.49%

N/A

Free Cash Flow

-$55.31M

-54.0%

Operating Cash Flow

-$55.07M

-53.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LEGNLegend Biotech Corporation
$22.71-1.43%
TVTXTravere Therapeutics, Inc.
$55.28-2.57%
XENEXenon Pharmaceuticals Inc.
$66.98-1.08%
RAREUltragenyx Pharmaceutical Inc.
$30.22-4.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
ONDSOndas
$6.65-0.06%
SOFISoFi Technologies
$17.32-0.03%

Questions About CELC

What is the current price of Celcuity?

Celcuity is trading at $88.29 per share.

What is the 52-week range for Celcuity?

Over the past 52 weeks, Celcuity has traded between $13.47 and $151.02.

How much debt does Celcuity have?

As of the most recent reporting period, Celcuity reported total debt of $323.44M.

How much cash does Celcuity have on hand?

Celcuity reported $145.19M in cash and cash equivalents in its most recent financial results.

What is Celcuity’s dividend yield?

Celcuity does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services